Tilray revenue soars 85% in 3Q as company takes aim at cannabis expansion
Higher operating expenses, expansion of international teams and costs related to its IPO accounted for an increase in losses
Company
Cronos Group Inc
NASDAQ:CRON
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach®, PEACE NATURALS®, and Lord Jones®.
114 stories · page 4 of 6
Cronos revenue nearly triples after Canada cannabis legalization, but swings to a loss for third quarter
On its list of quarterly highlights is a new partnership with Ginkgo Bioworks to produce cannabinoids through fermentation
Buds & Duds: Cannabis stocks were fired up after midterms, but end the week on a low note
Voters in Michigan, Missouri and Utah voted ‘yes’ on marijuana proposals in Tuesday’s election
Shorts to hike positions in cannabis majors Canopy Growth, Aurora Cannabis, Cronos Group and Tilray, says S3 Partners
Short-sellers are betting on a reversal in what they see as an overheated, overvalued cannabis sector
Buds & Duds: Cannabis stocks on a high after midterm wins and Sessions’ exit
Voters in Michigan, Missouri and Utah voted ‘yes’ on marijuana proposals Tuesday
Buds & Duds: Cannabis stocks riding high ahead of the US midterm election
Voters in Michigan, North Dakota, Missouri and Utah will vote on marijuana proposals Tuesday
Cannabis stocks end the week on a mixed note as some major players take a hit
Big names in cannabis, including Aurora Cannabis and Cronos, fared well Friday afternoon
Canadian cannabis company Aphria plans to list on NYSE to boost liquidity, investor interest
The Ontario-based cannabis company filed with the SEC last week but has yet to set a date for its trading debut
Cronos Group partners with foundation for cannabinoid-based skin care treatments
Research will look into potential applications of cannabinoids to regulate skin health and treat skin disorders
Veritas kicks off coverage of Canada's cannabis industry with Sell ratings Canopy Growth, Aphria, Aurora Cannabis and Cronos
'Our analysis suggests that the market still lacks perspective when it comes to the size, shape and sustainability of Canada’s proverbial pot of gold,' argues analyst Stuart Rolfe
Andrew Left’s Citron Research sets $65 price target for Pyxus International stock, says it's 'a perfect hedge'
Pyxus shares soared after the short-seller released a report saying Pyxus would be the greatest beneficiary if tobacco giant Altria takes a stake in cannabis grower Aphria
Andrew Left’s Citron Research is shorting cannabis companies left and right, but not this one
The tobacco company’s Canadian subsidiary recently received a cannabis cultivation license from Health Canada
Tilray and Cronos Group stock fall in holiday-tinged market dealings
Tilray has been rocked by volatile trading and Cronos has signed a string of partnerships in the cannabis space; New Age Beverage and DAVIDsTEA tumbled as well
Short-seller Andrew Left’s Citron Research doubles down on Namaste Technologies, calls it a 'fraud'
Citron Research published a seven-page report that it claims proves the cannabis company is a fraud
Short-seller Andrew Left’s Citron Research sets sights on India Globalization Capital
The infrastructure-meets-pharmaceutical company recently announced a line of CBD-infused energy drinks
Why America's cannabis companies are flocking to Canada to woo public investors
The Canadian Securities Exchange is becoming a wildly popular destination for US cannabis companies rejected by the NYSE and Nasdaq
Andrew Left of Citron Research looking to create cannabis-fund, says Bloomberg
The fund would invest in Canadian-listed cannabis companies
Buds & Duds: Cannabis stocks have a bumpy Tuesday but perk up by end of trading
The pot thickens: Cannabis stocks had a choppy Tuesday, as the market continues to fuel speculation with the potential for big winners -- and losers
Buds & Duds: Not a manic Monday as cannabis stocks calm down; Canopy Growth shares perk up on Manitoba news
Cannabis stocks had a quiet Monday overall when it comes to significant stock movements
Aleafia Health secures a spot on Horizons Marijuana Life Sciences ETF
The company recently teamed up with Cronos to study the effects of medical cannabis on insomnia